-transparent.png){kind=logo}
The fate of 14C-labelled bromhexine (Bisolvon¿) in man following intravenous and oral administration was studied by investigation of the blood and plasma levels and the excretion profiles. Slight variations observed between the two administration routes are explained by the somewhat different distribution patterns resulting from the different "first path" after oral application (liver) and intravenous injection (tissues).
Related Publications
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
June 1988,
Arzneimittel-Forschung,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
February 1970,
The Journal of pharmacy and pharmacology,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
April 1956,
Blood,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
October 1979,
British journal of clinical pharmacology,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
November 2000,
Anti-cancer drugs,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
November 1972,
Xenobiotica; the fate of foreign compounds in biological systems,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
December 1970,
The Journal of pharmacy and pharmacology,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
November 1983,
The Indian journal of medical research,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
June 1997,
Xenobiotica; the fate of foreign compounds in biological systems,
R Jauch, and
R Hankwitz, and
D Maass, and
R Wollmann
January 1965,
The American review of respiratory disease,
